secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0001193125-24-072689
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Homology Medicines approves 1-for-18 reverse stock split effective March 25 in connection with Q32 merger
--------------------------------------------------------------------------------

- Board approved reverse stock split at 1-for-18 ratio; every 18 shares combine into one.
- Reverse split effective at market open on March 25, 2024; Certificate of Amendment filed March 22.
- No fractional shares issued; stockholders receive cash in lieu based on March 22 closing price.
- Reverse split is a condition to closing of the merger with Q32 Bio Inc.
- Post-split common stock trades under new CUSIP 746964105.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312524072689/0001193125-24-072689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312524072689/d808597d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-072689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer